drugset / Trial / NCT05933395
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Timeline
- Start
- 2024-09-23
- Primary completion
- 2030-10
- Completion
- 2031-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Alpelisib | Small molecule | 300 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Neratinib | Small molecule | 240 mg | Oral |